Heart rhythm
Authors: Han FT, Scheinman M
The Lancet. Oncology
Authors: Tolaney SM, Tarantino P, Graham N, Tayob N, Par? L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP
Blood
Authors: Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, Frank MJ, Johnston LJ, Miklos DB, Muffly L, Negrin RS, Rezvani AR, Shiraz P, Shizuru JA, Weng WK, Binkley MS, Hoppe RT, Advani RH, Arai S
The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved significantly over the past decade following the approval of brentuximab vedotin (BV) and the programmed death-1 (PD-1) inhibitors. We evaluated how outcomes and practice patterns have changed for R/R cHL patients who underwent autologous hematopoietic cell transplantation (AHCT) at our institution from 2011-2020 (N=183) compared to 2001-2010 (N=159) and evaluated prognostic factors for progression-free survival (PFS) and overall survival (OS) in both eras. OS was superior in the modern era (4-year estimates 89.1% vs 79.0%, HR 0.53, 95% CI 0.33-0.85, p=0.011) with a trend towards lower non-relapse mortality beyond 2 years post-transplant. Among patients who progressed after AHCT, 4-year post-progression survival increased from 43.3% to 71.4% in the modern era, reflecting increasing use of BV and the PD-1 inhibitors. In multivariable analysis for patients transplanted in the modern era, age ³45 years, primary refractory disease, and lack of complete remission pre-AHCT were associated with inferior PFS, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS (HR 0.21, 95% CI 0.05-0.80, p=0.030). Extranodal disease at relapse was associated with inferior OS (HR 3.12, 95% CI 1.25-7.77, p=0.014). Our study demonstrates improved survival for R/R cHL after AHCT in the modern era attributed to more effective salvage regimens allowing for better disease control pre-AHCT and improved outcomes for patients who progressed after AHCT. Excellent outcomes were observed with PD-1 inhibitor-based salvage regimens pre-AHCT and support a randomized trial evaluating immunotherapy in the second line setting.
View on PubMed
JAMA psychiatry
Authors: Hasin DS, Wall MM, Choi CJ, Alschuler DM, Malte C, Olfson M, Keyes KM, Gradus JL, Cerd? M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, Mannes Z, Sherman S, Saxon AJ
American journal of kidney diseases : the official journal of the National Kidney Foundation
Authors: Johansen KL, Chertow GM, Gilbertson DT, Ishani A, Israni A, Ku E, Li S, Li S, Liu J, Obrador GT, Schulman I, Chan K, Abbott KC, O'Hare AM, Powe NR, Roetker NS, Scherer JS, St Peter W, Snyder J, Winkelmayer WC, Wong SPY, Wetmore JB
Anesthesiology
Authors: Calabrese DR, London MJ
Circulation
Authors: Jose M Rodriguez Valadez, Malak Tahsin, Umesh Masharani, Meyeon Park, M.G. Myriam Hunink, Joseph Yeboah, Lihua Li, Ellerie Weber, Yan Li, Asem Berkalieva, Luuk Avezaat, Wendy Max, Kirsten E Fleischmann, Bart S Ferket
Circulation
Authors: John S Kim, Yifei Sun, Pallavi Balte, Mary Cushman, Russell P Tracy, Linda Styer, Michaela R Anderson, Norrina B Allen, Pamela Schreiner, Russell P Bowler, David Schwartz, Joyce Lee, Vanessa Xanthakis, Margaret Doyle, Alka M Kanaya, Mitchell S Elkind, Virginia J Howard, Victor Ortega, Prescott Woodruff, Shelley Cole, Nicholas Mantis, Monica Parker, R. Graham Barr, Elizabeth Oelsner, Ryan Demmer
Circulation
Authors: Pallavi Balte, Yifei Sun, Asma Sharaf, Akshaya Krishnaswamy, Alexander Arynchyn, Elizabeth A Regan, Vasan S Ramachandran, David Schwartz, Wendy S Post, Alka M Kanaya, Mitchell Elkind, Virginia J Howard, Victor Ortega, Prescott Woodruff, Shelley Cole, Elizabeth C Oelsner
Clinical genitourinary cancer
Authors: Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR
